

Selected Trials of Long-Acting Injectables for Prevention and/or Treatment of HIV (April 2014)

Active LA Drug	Other Name	Developer	Phase of Research	Trial Name	Population	Class of Drug
Long-acting TMC278	Rilpivirine (RPV), Edurant	Janssen	Phase II	HPTN 076 (planned)	HIV-negative at risk women	Nonnucleoside reverse transcriptase inhibitor
Long-acting GSK744	GSK1265744	GlaxoSmithKline (GSK)	Phase IIa	ÉCLAIR (ongoing); HPTN 077 (planned)	HIV-negative at-risk men, MSM; HIV-negative at risk women and men	Integrase strand transfer inhibitor
Ibalizumab	TMB-355, monoclonal antibodies	Aaron Diamond AIDS Research Center	Phase I	TMB-108 (completed)	HIV-negative women and men	Entry inhibitor
Oral TMC278 and GSK744	Rilpivirine (RPV), Edurant and Tivicay	Janssen and GlaxoSmithKline (GSK)	Phase II	LATTE (ongoing)	HIV-positive men (96%) and women	Nonnucleoside reverse transcriptase inhibitor plus integrase strand transfer inhibitor

For a complete list of long-acting injectable trials, visit www.avac.org/long-acting-injectables.
 A full list of HIV prevention clinical trials is available at www.avac.org/pxrd.